Teva unseats Pfizer
Executive Summary
Based on prescriptions dispensed, Teva has become the top pharmaceutical company in the U.S. following its merger with Ivax. Pro-forma 2005 numbers from IMS put the combined company at 364 mil. annual scripts, versus 324 mil. for previously number one Pfizer, which is starting to emphasize its fast-growing Greenstone generic business (1"The Pink Sheet" Feb. 20, 2006, p. 21). In terms of sales, Teva will be the 14th largest pharma company in the U.S. The company expects the $7.4 bil. acquisition will aid its geographic expansion and price negotiations (2"The Pink Sheet" Aug. 1, 2005, p. 19)...
You may also be interested in...
Teva/Ivax Merger Will Create Significant Pricing Flexibility In Generics
Teva is prepared to leverage its $7.4 bil. acquisition of Ivax to offer the lowest prices on generic drugs "if need be," Ivax Chairman Phillip Frost said July 26 during a call regarding the deal
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.